



28 February 2018

Hon. Greg Walden  
Chairman  
2125 Rayburn HOB  
Washington, DC 20515

Hon. Frank Pallone  
Ranking Member  
2322A Rayburn HOB  
Washington, DC 20515

Dear Chairman Walden & Ranking Member Pallone –

**braeburn**

47 Hulfish St, Suite 441  
Princeton, NJ 08542

On behalf of Braeburn, I am writing to thank you for your leadership on the Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018, which will make long overdue updates to federal law to improve the dispensing of implantable and injectable therapies. We share your goal of expanding access to treatments for patients with Opioid Use Disorder, and applaud your efforts to make abuse, misuse and diversion more difficult.

Braeburn is dedicated to developing evidence-based treatments to help stop the opioid epidemic and save American lives. Braeburn provides the healthcare provider with a platform of addiction treatment medications that help promote adherence and are expected to be less prone to abuse and diversion than daily addiction treatments.

The Ensuring Patient Access to Substance Use Disorder Treatments Act will expand access to practitioner-administered treatments, which will help to ensure proper delivery and medication adherence, while potentially minimizing risks of diversion, misuse and accidental pediatric exposure.

The Controlled Substances Act, when originally enacted, did not foresee these innovative new products, and requires that a product must be dispensed to the patient for whom it was written. This requirement creates an unnecessary barrier to next generation treatments.

We thank you again for your leadership on this critical issue.

Best,

Mike Derkacz  
President & CEO